Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.54 |
| ▸ | ACACB | O00763 | 12/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.49 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | NQO1 | P15559 | 1/20 | 0.47 |
| ▸ | PPARA | Q07869 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13663555 | 1.00 | PARP10 (0.54) | PARP10ACACBALDH1A1ITGB3ITGA2B | |
| SCHEMBL6865304 | 0.88 | ACACB (0.54) | PARP10ACACBITGB3ITGA2BMEN1 | |
| SCHEMBL14355744 | 0.88 | ACACB (0.54) | PARP10ACACBITGB3ITGA2BMEN1 | |
| SCHEMBL15593886 | 0.87 | ITGB3 (0.57) | ACACBITGB3ITGA2BCYP1A2 | |
| SCHEMBL16816291 | 0.87 | ITGB3 (0.57) | ACACBITGB3ITGA2BCYP1A2 | |
| SCHEMBL158880 | 0.87 | ITGB3 (0.64) | PARP10ACACBALDH1A1ITGB3ITGA2B | |
| SCHEMBL158881 | 0.87 | ITGB3 (0.64) | PARP10ACACBALDH1A1ITGB3ITGA2B | |
| SCHEMBL2036599 | 0.87 | ITGB3 (0.64) | PARP10ACACBALDH1A1ITGB3ITGA2B | |
| Hydrochloric Acid SCHEMBL16816881 | 0.86 | ITGB3 (0.56) | ACACBITGB3ITGA2BCYP1A2 | |
| Hydrochloric Acid SCHEMBL16816877 | 0.86 | ITGB3 (0.56) | ACACBITGB3ITGA2BCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100534976-C | S-1-(4-ethoxybenzyl)-3-azapentane-1,5 diamine preparation method | JIANGSU INST OF NUCLEAR MED (CN) | 2009-09-02 | — | — | CN | disclosed |
| US-20090176967-A1 | Conjugation of FVII | NOVO NORDISK HEALTHCARE A/G (CH) | 2009-07-09 | — | — | US | disclosed |
| CN-101007775-A | S-1-(4-ethoxybenzyl)-3-azapentane-1,5 diamine preparation method | JIANGSU INST OF NUCLEAR MED (CN) | 2007-08-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176967-A1 | Conjugation of FVII | F13B, F13A1, FGB | PARP10 2011/4885ACACB 2868/4885ALDH1A1 4528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.